

RESEARCH

Open Access



Eicosapentaenoic acid prevents the progression of intracranial aneurysms in rats

Yu Abekura^{1,2,3}, Isao Ono^{1,2,3}, Akitsugu Kawashima⁴, Katsumi Takizawa⁵, Hirokazu Koseki^{1,3,6}, Haruka Miyata^{1,3,7}, Kampei Shimizu^{1,2,3}, Mieko Oka^{1,3,8}, Mika Kushamae^{1,3,9}, Susumu Miyamoto², Hiroharu Kataoka², Akira Ishii² and Tomohiro Aoki^{1,3*}

Abstract

Background: As subarachnoid hemorrhage due to rupture of an intracranial aneurysm (IA) has quite a poor outcome despite of an intensive medical care, development of a novel treatment targeting unruptured IAs based on the correct understanding of pathogenesis is mandatory for social health.

Methods: Using previously obtained gene expression profile data from surgically resected unruptured human IA lesions, we selected G-protein coupled receptor 120 (GPR120) as a gene whose expression is significantly higher in lesions than that in control arterial walls. To corroborate a contribution of GPR120 signaling to the pathophysiology, we used an animal model of IAs and examine the effect of a GPR120 agonist on the progression of the disease. IA lesion was induced in rats through an increase of hemodynamic stress achieved by a one-sided carotid ligation and induced hypervolemia. Eicosapentaenoic acid (EPA) was used as an agonist for GPR120 in this study and its effect on the size of IAs, the thinning of media, and infiltration of macrophages in lesions were examined.

Result: EPA administered significantly suppressed the size of IAs and the degenerative changes in the media in rats. EPA treatment also inhibited infiltration of macrophages, a hallmark of inflammatory responses in lesions. In in vitro experiments using RAW264.7 cells, pre-treatment of EPA partially suppressed lipopolysaccharide-induced activation of nuclear factor-kappa B and also the transcriptional induction of monocyte chemoattractant protein 1 (MCP-1), a major chemoattractant for macrophages to accumulate in lesions. As a selective agonist of GPR120, TUG-891, could reproduce the effect of EPA in RAW264.7 cells, EPA presumably acted on this receptor to suppress inflammatory responses. Consistently, EPA remarkably suppressed MCP-1 expression in lesions, suggesting the in vivo relevance of in vitro studies.

Conclusions: These results combined together suggest the potential of the medical therapy targeting GPR120 or using EPA to prevent the progression of IAs.

Keywords: Intracranial aneurysm, Eicosapentaenoic acid, GPR120

* Correspondence: tomoaoki@ncvc.go.jp

¹Department of Molecular Pharmacology, Research Institute, National Cerebral and Cardiovascular Center, Suita, Osaka 564-8565, Japan

³Core Research for Evolutional Science and Technology (CREST) from Japan Agency for Medical Research and Development (AMED), National Cerebral and Cardiovascular Center, Osaka, Japan

Full list of author information is available at the end of the article



© The Author(s). 2020 **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Background

Subarachnoid hemorrhage (SAH) mainly caused by the rupture of an intracranial aneurysm (IA) has the mortality rate as high as 50% within 1 month from the onset [1, 2], making this disease being one of the most serious health problems. The incidence of SAH is 9/100,000 persons per year worldwide [3] but, in Finland and Japan, the incidence reaches 20~30/100,000 persons per year [3, 4]. Because the prevalence of unruptured IAs in general population is high, 2–4% [5], and IA can cause the lethal SAH after rupture, the preemptive treatment of unruptured IAs to prevent the onset of SAH is mandatory for social health. Although IAs are often found before rupture during brain check or so, surgical interventions such as clipping and coil embolization are applied only to the selected patients whose IAs are considered at high risk of rupture depending on the size, shape, and location of IAs [6]. In addition, surgical interventions have the potential risk of complication and thus occasionally result in unfavorable outcome. Moreover, because of no effective medical treatment available, patients without surgical indication or followed up without surgical interventions do not have any choice but to rule out the progression of IAs by a long-term follow-up. The establishment of less-invasive medical treatment to prevent the progression and the rupture of IAs is therefore a matter to be urgently addressed.

Considered with the current situation surrounding IA treatment as described above, the inquisition of a novel therapeutic target to develop drugs to treat IAs, especially to prevent the progression, is crucial for social health. The experimental studies have clarified the crucial role of nuclear factor-kappa B (NF- κ B)-mediated inflammatory responses in the pathogenesis of IAs [7–9]. The pharmacological measures interfering NF- κ B pathway may thus become a reasonable strategy as the treatment of IAs. To explore a therapeutic target, we selected G-protein coupled receptors (GPCRs), that were upregulated in IA walls compared with those in the control arterial walls, as candidates [10] because GPCRs are on the top of signal transduction cascades and, thereby, inhibition of these receptors is presumably efficient and effective. We, in the present study, have then verified the potential of one of such upregulated GPCRs in lesions, GPR120, as a therapeutic target because GPR120, a receptor of ω 3 fatty acids, could inhibit NF- κ B activation [11]. Stimulation of GPR120 with its ligand induces the formation of the GPR120/ β -arrestin-2 complex and then β -arrestin-2 traps transforming growth factor- β (TGF- β) activated kinase 1 binding protein (TAB1), leading to the inhibition of TGF- β activated kinase 1 (TAK1) which activates inhibitor of κ B kinase subunit β (IKK β) [11, 12].

Methods

Human specimen and immunohistochemistry

Human IA samples and control arterial walls (superficial temporal artery or middle meningeal artery) were dissected during microsurgical clipping of unruptured IAs with the written informed consent. Dissected specimens were fixed in formalin solution and embedded in paraffin. Four-micrometer-thick slices were then prepared for histopathological and immunohistochemical analyses. After deparaffinization and blocking with 3% donkey serum (Jackson ImmunoResearch, West Grove, PA), slices were incubated with primary antibodies overnight at 4 °C in a humidified chamber, followed by incubation with secondary antibodies conjugated with fluorescence dye (Jackson ImmunoResearch) for additional 1 h at room temperature in a humidified chamber. Finally, fluorescent images were acquired on a confocal fluorescence microscope system (FV1000, Olympus, Tokyo, Japan). Scanning was performed using a UPLSAPO 40 $\times$ /NA 0.9 objective (Olympus) at a resolution of 1024 $\times$ 1024 pixels with a field of view of 317 μ m square. Maximal intensity projections along the Z-axis of at least five images at optimal thickness from each slide were obtained using a FLUOVIEW (version 4.02, Olympus). Images were processed in brightness and contrast using an Adobe Photoshop Elements14 (Adobe Systems, San Jose, CA).

In some experiments, secondary antibodies conjugated with horseradish-peroxidase (Vector Laboratories, Burlingame, CA) were used and immune complexes were detected with either a Vectastain Elite ABC kit (Vector Laboratories) or an EnVision kit (DAKO, Glostrup, Denmark) using 3,3'-diaminobenzidine (DAB) as a substrate. Images were acquired using a light microscope (IX71, Olympus) equipped with a UPlanFLN 4 $\times$ /NA 0.13 objective (Olympus), UPlanFLN 10 $\times$ /NA 0.3 objective (Olympus), or LUCPlanFLN 40 $\times$ /NA 0.6 objective (Olympus) at a resolution of 1360 $\times$ 1024 pixels with a field of view of 4.4 $\times$ 3.3 mm, 1.8 $\times$ 1.3 mm, or 438.6 $\times$ 330.2 μ m, respectively. Images were captured using a digital camera (DP72, Olympus) and a cellSens Standard (version 1.6, Olympus). The brightness and contrast of the images were adjusted in an Adobe Photoshop Elements14 (Adobe Systems).

Primary antibodies used are as follows: rabbit polyclonal anti-GPR120 antibody (dilution 1:900, #LS-A2003, Life-Span BioSciences, Inc., Seattle, WA), mouse monoclonal anti-CD31 antibody (1:100, #M0823, DAKO), mouse monoclonal anti-smooth muscle α -actin (SMA) antibody (1:200, #M0851, DAKO), and mouse monoclonal anti-CD68 antibody (1:100, #M0814, DAKO).

The secondary antibodies used are as follows: Alexa Fluor 488-conjugated donkey anti-rabbit IgG (H + L)

antibody (1:100, #A21206, Invitrogen, Carlsbad, CA) and Alexa Fluor 594-conjugated donkey anti-mouse IgG (H + L) antibody (1:100, #A21203, Invitrogen).

Rodent IA models and histological analysis of induced IA

Male Sprague–Dawley rats were purchased from Japan SLC ($n = 84$, Shizuoka, Japan). Animals were maintained on a light/dark cycle of 12 h/12 h, and had a free access to chow and water.

A total of 24 rats were used to examine the pharmacokinetics of eicosapentaenoic acid (EPA). The whole blood was transcardially collected from four rats before EPA administration under intraperitoneal injection of a lethal dose of pentobarbital sodium (200 mg/kg). The remaining 20 rats were randomly divided into the two groups; vehicle-treated group and the EPA-treated group. Ten rats in each group were administrated 1000 mg/kg EPA or olive oil as a vehicle. The whole blood was then collected transcardially at 1 h ($n = 3$), 6 h ($n = 3$), or 24 h ($n = 4$) after the administration.

To induce IA, under general anesthesia by intraperitoneal injection of pentobarbital sodium (50 mg/kg), 7-week-old male rats were subjected to ligation of the left carotid artery and hypervolemia achieved by the combination of a high salt diet and ligation of the left renal artery. Immediately after above surgical manipulations, the chow was completely switched from a normal to the special one containing 8% sodium chloride and 0.12% 3-aminopropionitrile (Tokyo Chemical Industry, Tokyo, Japan), an inhibitor of lysyl oxidase that catalyzes the cross-linking of collagen and elastin. 3-Aminopropionitrile was added in a chow to reduce the stiffness of arterial walls and thus facilitate degenerative changes of the media. The special chow was refilled twice a week, and all rats kept free access to water and the special chow after surgical manipulations during the observation period. A total of 60 rats were subjected to surgical manipulations and 30 rats among them were used for examining the effect of EPA on IAs. Another 30 rats were used to determine the intake of EPA in the plasma. These 30 rats were randomly allocated into three groups: the olive oil-administered group (vehicle-treated group, $n = 10$), the 100 mg/kg/day EPA-administered group ($n = 10$), or the 1000 mg/kg/day EPA-administered group ($n = 10$). Dead animals during the observation period were excluded from the analysis. Blood pressure was measured by the tail-cuff method on the 11th day after surgical manipulations. The rats were placed in a cylindrical warmer (#THC-31, Softron, Tokyo, Japan) and kept at 37 °C during the measurement. Blood pressure were then measured using an automatic measurement device (#BP-98A, Softron) without any anesthesia and its value was defined as the average of three consecutive measurements. Body weight was measured twice; before surgical manipulations and on the

day of sacrifice. At times indicated in the corresponding figure legends or results after above surgical manipulations, animals were deeply anesthetized by intraperitoneal injection of pentobarbital sodium (200 mg/kg), and transcardially perfused with 4% paraformaldehyde solution. The bifurcation site of anterior cerebral artery (ACA)-olfactory artery (OA) including the induced IA lesion was then stripped, and serial frozen sections were made. Histopathological examination to evaluate IAs was done after Elastica van Gieson staining which visualizes internal elastic lamina (IEL) and induced IAs were histologically defined as a lesion with the disruption of IEL [8, 13]. The area of IA was measured using ImageJ software (version 1.51s, <https://imagej.nih.gov/ij/index.html>) [14] using the section including the maximum diameter of the lesions.

EPA

EPA (Epadel (ethyl icosapentate), Mochida Pharmaceutical Co., LTD., Tokyo, Japan) was commercially available and we thus purchased this drug. Immediately before administration, EPA was extracted from Epadel capsule and then diluted with olive oil to the concentration of 25 mg/ml or 250 mg/ml. Then, 4 ml/kg of EPA solution was orally administered by gavage. The dose of EPA was determined by referencing the previous reports in a rat model [15–17]. For the measurement of plasma concentration of EPA, docosahexaenoic acid (DHA), and also arachidonic acid (AA), arterial blood was transcardially collected with an 18-gauge needle at 24 h after the last administration of EPA or vehicle after intraperitoneal injection of a lethal dose of pentobarbital sodium (200 mg/kg). The collected blood (5–8 ml per animal) was heparinized and the plasma was then collected. The plasma samples were stored at –80 °C until measurement. The plasma concentration of EPA, DHA, and AA was measured by gas chromatography at SRL Inc. (Tokyo, Japan).

Immunohistochemistry

At the indicated period after surgical manipulations, 5- μ m-thick frozen sections were prepared from dissected IA lesions as described above. After blocking with 3% donkey serum (Jackson ImmunoResearch), slices were incubated with primary antibodies overnight at 4 °C in a humidified chamber, followed by incubation with secondary antibodies conjugated with a fluorescence dye (Jackson ImmunoResearch) for additional 1 h at room temperature in a humidified chamber. The slices were then mounted with by a ProLongR Gold antifade reagent with DAPI (4',6-diamidino-2-phenylindole dihydrochloride) (Invitrogen), a fluorescence dye that binds to double-stranded DNA and then visualizes nuclei. Finally, fluorescent images were acquired on a confocal fluorescence microscope system (FV1000, Olympus). Scanning

was performed using a UPLSAPO 40×/NA 0.9 objective (Olympus) or 60×/NA 1.35 oil immersion objective (Olympus) at a resolution of 1024 × 1024 pixels with a field of view of 317 μm or 211 μm square, respectively. Maximal intensity projections along the Z-axis of at least five images at optimal thickness from each slide were obtained using a FLUOVIEW (version 4.02, Olympus). Images were processed in brightness and contrast using an Adobe Photoshop Elements14 (Adobe Systems).

The primary antibodies used are as follows: Cy3-conjugated mouse monoclonal anti-smooth muscle α-actin antibody (1:200, #6198-2ML, Sigma Aldrich, St. Louis, MO), mouse monoclonal anti-CD68 antibody (1:100, #31630, Abcam, Cambridge, UK), and rabbit polyclonal anti-C-C motif chemokine 2 (CCL2) antibody (1:100, #ab9779, Abcam).

The secondary antibodies used are as follows: Alexa Fluor 488-conjugated donkey anti-mouse IgG (H + L) antibody (1:100, #A21202, Invitrogen) and Alexa Fluor 488-conjugated donkey anti-rabbit IgG (H + L) antibody (1:100, #A21206, Invitrogen).

Macrophage count

Macrophage was defined as the cell positive for CD68 in immunohistochemistry. The number of infiltrated macrophages in each lesion was calculated as a cell count present around the dome of induced aneurysms. Independent two researchers (Y.A. and I.O.) who did not know the group allocation counted the number of CD68-positive cells in each slide and the results were compared. When disagreed, the researchers checked and discussed the image together, and determined the number of positive cells.

Plasma concentration of Resolvin E1

Plasma was prepared from rats administered for 12 days with 1000 mg/kg/day of EPA. The plasma was collected at 24 h after the last administration of EPA as described above. And the concentration of Resolvin E1 was measured by a Rat Resolvin E1 ELISA Kit (#MBS2601346, MyBioSource, Inc., San Diego, CA) according to the manufacturer's instructions.

Cell culture and treatment with compounds targeting GPR120

The Raw264.7 cell line (ATCC, Manassas, VA), a mouse monocyte/macrophage cell line, was used due to endogenous expression of functional GPR120 [11]. Cells were cultured in Dulbecco's modified Eagle medium (DMEM) (FUJIFILM Wako Pure Chemical Corporation, Osaka, Japan) supplemented with 10% fetal bovine serum. In some experiments using EPA, DMEM without phenol-red (FUJIFILM Wako Pure Chemical Corporation) was used. Cells were pre-treated with GPR120

agonists, EPA (Mochida Pharmaceutical Co., Ltd.) or TUG-891 (Cayman Chemical, Ann Arbor, MI), before stimulation with lipopolysaccharide (LPS) (Lot. 123M4052V, # L2654, Sigma Aldrich).

Western blot analysis

Whole cell lysate was prepared by a RIPA buffer (Sigma Aldrich) supplemented with proteinase and phosphatase inhibitors (Roche, Indianapolis, IN). Protein concentration was, then, determined by a bicinchoninic acid (BCA) method (Pierce BCA Protein Assay Kit, Thermo Scientific, Waltham, MA). After sodium dodecyl sulfate-poly-acrylamide gel electrophoresis (SDS-PAGE), separated proteins were transferred to a PDVF membrane (Hybond-P, GE healthcare, Buckinghamshire, UK) and blocked with an ECL plus blocking agent (GE healthcare). The membranes were incubated with primary antibodies followed by incubation with an anti-IgG antibody conjugated with horseradish peroxidase (GE healthcare). Finally, the signal was detected by a chemiluminescent reagent (ECL Prime Western Blotting Detection System, GE healthcare). α-Tubulin was served as an internal control.

Antibodies used in Western blot analysis are as follows: rabbit monoclonal anti-p65 antibody (Cell Signaling Technology, Danvers, MA), rabbit monoclonal anti-phospho NF-κB p65 (Ser536) antibody (Cell Signaling Technology), and mouse monoclonal anti-α-tubulin antibody (Sigma Aldrich).

Quantitative real time-PCR analysis

RNA purification from cultured cells and reverse transcription were done using a RNeasy Plus Mini Kit (QIAGEN, Hilden, Germany) and a High-capacity cDNA Reverse Transcription Kit (Life Technologies Corporation, Carlsbad, CA) according to manufacturers' instructions. For the quantification of gene expression, RT-PCR was performed on a Real Time System a Light-Cycler 480 (Roche) with a TB Green Premix Ex Taq II (TAKARA BIO INC., Shiga, Japan) using the expression of α-actin (*Actb*) as an internal control. For quantification, the second derivative maximum method was used for crossing point determination.

Primer sets used in the present experiment are as follows: forward 5'-GTCTCTGCCGCCCTTCTGTG-3' and reverse 5'-AGGTGACTGGGGCATTGATTG-3' for *Ccl2* which encodes monocyte chemoattractant protein 1 (MCP-1), and 5'-ACGACCAGAGGCATACAGGGA-3' and 5'-CCCTAAGGCCAACCGTGAAA-3' for *Actb*.

Statistics

Data are shown as mean ± SD or by box-and-whisker plots. Differences between the two groups were examined using a non-parametric Mann-Whitney test by a

JMP Pro 13 (SAS Institute Inc., Cary, NC). Statistical comparisons between more than two groups were conducted using a Kruskal-Wallis test followed by the post-hoc Steel-Dwass test by a JMP Pro 13 (SAS Institute Inc.). We used above non-parametric tests in the present study because the sample size was not enough to assess whether the data sets were normally distributed or not by a Shapiro-Wilk test. The Jonckheere-Terpstra test was performed to confirm a dose-response relationship using an EZR software (Saitama Medical Center, Jichi Medical University, Saitama, Japan, <http://www.jichi.ac.jp/saitama-sct/SaitamaHP.files/statmedEN.html>) [18]. A p value smaller than 0.05 was defined as statistically significant.

Results

Over-expression of *GPR120* in human IA walls revealed by RNA sequencing analysis and protein expression of *GPR120* in human IA lesions

We picked up *GPR120* (free fatty acid receptor 4 (FFAR4)) as a putative therapeutic target from GPCRs whose expression

was significantly upregulated in human unruptured IA lesions ($n = 4$) compared with those in control arterial walls ($n = 3$) ($p = 7.95E^{-10}$) from previously obtained comprehensive gene expression profile data by RNA-sequencing analysis [10] (ID number #PRJNA553307 at BioProject database (<http://www.ncbi.nlm.nih.gov/bioproject>)). To confirm whether over-expression of *GPR120* is indeed reflected in protein expression, we performed immunohistochemical analysis using both human IA specimens ($n = 4$) and control arterial walls ($n = 3$). In control arterial walls, signals for *GPR120* in immunostaining were detected throughout the media and sparsely in the adventitia but not in the intima (Fig. 1 and Additional file 1: fig. S1). In IA lesions, signals for *GPR120* in the media became sparse, presumably due to loss of medial smooth muscle cells, but signals in the intima were induced (Fig. 1 and Additional file 1: fig. S1). Positive signals for *GPR120* staining were co-localized with the marker of smooth muscle cells, SMA, both in IA lesions and control arterial walls (Fig. 2). In addition, other positive signals for *GPR120* staining observed in IA walls were co-localized with the marker of macrophages, CD68, in




Fig. 1 Expression of *GPR120* in human IA lesion and the control arterial wall. The representative images of immunostaining of specimens from human IA lesion (the upper panels) and the control arterial wall (middle meningeal artery, the lower panels) for *GPR120* are shown. The magnified images corresponding to the squares in the left panels are also shown on a right. Bar; 200 μ m. The arrow head indicates the endothelial cells where *GPR120* expression is induced




Fig. 2 Induction of GPR120 expression in endothelial cells and macrophages of human IA lesions. The representative images of immunostaining of specimens from human IA lesion (the upper panels) and the control arterial wall (middle meningeal artery, the lower panels) for GPR120 (green), CD31, a marker for endothelial cells (red in **a**), CD68, a marker for macrophages (red in **b**) or smooth muscle α -actin (SMA), a marker for smooth muscle cells (red in **c**), nuclear staining by DAPI (blue) and merged images are shown. The magnified images corresponding to the squares in the left panels are also shown on a right. In **d**, the image of immunostaining without a primary antibody is shown as a negative control study. Bar; 10 μ m. Note the induction of GPR120 in CD31-positive endothelial cells and CD68-positive macrophages while expression in smooth muscle cells is constitutive

the adventitia or the marker of endothelial cells, CD31, in the intima (Fig. 2), suggesting the expression of GPR120 in macrophages and the induction of this receptor in endothelial cells during the progression of the disease.

Effect of a ligand of GPR120, EPA, on the progression of IAs induced in a rat model

We selected EPA as an agonist for GPR120 [11, 19] because EPA is the already-approved drug for a clinical usage. We first examined the temporal change of the

plasma concentration of EPA after the oral administration of this compound to confirm that EPA orally administered was certainly taken into the plasma in rats. The plasma concentration of EPA before administration was $32.8 \pm 2.7 \mu\text{g/ml}$ ($n = 4$). The plasma concentration of EPA was certainly and significantly increased by the oral administration of EPA (1000 mg/kg) compared with the concentration in vehicle-treated group (1 h, 38.2 ± 2.0 vs. $139.0 \pm 26.1 \mu\text{g/ml}$, vehicle-treated group ($n = 3$) vs. 1000 mg/kg/day-administered group ($n = 3$), $p = 0.049$; 6 h, 28.4 ± 1.4 vs. $241.0 \pm 66.2 \mu\text{g/ml}$, vehicle-treated group ($n = 3$) vs. 1000 mg/kg/day-administered group ($n = 3$), $p = 0.049$; 24 h, 34.7 ± 6.6 vs. $114.8 \pm 12.4 \mu\text{g/ml}$, vehicle-treated group ($n = 4$) vs. 1000 mg/kg/day-administered group ($n = 4$), $p = 0.020$) (Additional file 1: fig. S2 left). Because DHA is a derivative of EPA [20, 21], the plasma concentration of DHA was also measured to rule out the effect of DHA when EPA was administered. We then found that the plasma concentration of DHA was not increased by the oral administration of EPA (Additional file 1: fig. S2 right). We thereby administered 100 mg/kg/day or 1000 mg/kg/day EPA to the rat model of IAs and again examined the plasma concentration of EPA or related factors on the 5th day after surgical manipulations to induce IAs. We confirmed the increase of EPA (vehicle-treated group, $16.3 [12.3-29.9] \mu\text{g/ml}$, $n = 9$; 100 mg/kg/day-administered group, $32.2 [28.8-34.2] \mu\text{g/ml}$, $n = 8$; 1000 mg/kg/day-administered group, $74.3 [55.6-97.9] \mu\text{g/ml}$ (median [interquartile range]), $n = 9$; vehicle-treated group ($n = 9$) vs. 1000 mg/kg/day-administered group ($n = 9$), $p = 0.0012$, 100 mg/kg/day-administered group ($n = 8$) vs. 1000 mg/kg/day-administered group ($n = 9$), $p = 0.0026$) and also the elevation of EPA/AA ratio in a dose-dependent manner ($p = 3.80 \times 10^{-7}$, the Jonckheere-Terpstra test) (Fig. 3a). The body weight was significantly increased during the observation period in all groups examined (vehicle-treated group, 234.0 ± 5.2 vs. 280.4 ± 16.1 g, pre-treatment vs. post-treatment, $n = 9$, $p = 0.0039$; 100 mg/kg/day-administered group, 226.6 ± 6.8 vs. 269.8 ± 9.6 g, $n = 10$, $p = 0.002$; 1000 mg/kg/day-administered group, 233.8 ± 4.1 vs. 273.3 ± 17.0 g, $n = 9$, $p = 0.0039$). Also the administration of EPA did not influence the systolic blood pressure as well (Additional file 1: fig. S3). On the 12th day after IA induction, all rats examined developed IAs characterized by the disruption of an internal elastic lamina in Elastica van Gieson staining (Fig. 3b). Three of 30 rats (10%) surgically manipulated died on the 3rd, 7th, and 11th day after the manipulations, and these animals were excluded from the analyses (vehicle-treated group, $n = 2$, 1000 mg/kg/day-administered group, $n = 1$). Thereby, the mortality rate during the observation period was 2/10 (20%) in vehicle-treated group, 0/10 (0%) in 100 mg/kg/day-


administered group, and 1/10 (10%) in 1000 mg/kg/day-administered group. Though the incidence of IAs was not influenced by the administration of EPA, the size of the lesions was significantly suppressed in a dose-dependent manner ($p = 0.012$, the Jonckheere-Terpstra test) (vehicle-treated group, $264.3 [222.1-415.3] \mu\text{m}^2$, $n = 8$; 100 mg/kg/day-administered group, $247.9 [138.9-349.5] \mu\text{m}^2$, $n = 10$; 1000 mg/kg/day-administered group, $97.7 [29.5-228.3] \mu\text{m}^2$, $n = 9$; vehicle-treated group vs. 1000 mg/kg/day-administered group, $p = 0.037$) (Fig. 3b, c).

We used EPA as an agonist for GPR120. However, as well-known, EPA exerts its action not only via GPR120 as an agonist but also via the formation of the metabolite, Resolvin, with a potent anti-inflammatory effect [22–27]. We therefore examined the concentration of Resolvin E1 in the plasma collected from EPA-administered animals. The plasma concentration of Resolvin E1 in animals treated with 1000 mg/kg/day of EPA for 12 days was rather significantly lower than that in the vehicle-treated group ($2.60 [1.36-4.30]$ vs. $1.03 [0.56-1.43]$ ng/ml, vehicle-treated group ($n = 8$) vs. 1000 mg/kg/day-administered group ($n = 9$), $p = 0.048$) (Fig. 3d), supporting that the suppressive effect of EPA on the progression of IAs was via GPR120.

Effect of EPA on degenerative changes of media and inflammatory responses in IA lesions

We, next, examined the effect of EPA on degenerative changes of media and inflammatory responses in IA lesions, one of the hallmarks reflecting the disease progression [28, 29]. The thinning of medial smooth muscle cell layer in lesions visualized by immunohistochemistry for a smooth muscle cell marker, SMA, was significantly suppressed by the administration of EPA (thickness of the thinnest portion in lesions; $3.10 [2.23-6.60]$ vs. $8.83 [5.85-11.7] \mu\text{m}$, vehicle-treated group ($n = 8$) vs. 1000 mg/kg/day-administered group ($n = 9$), $p = 0.0168$, $4.23 [3.76-5.67]$ vs. $8.83 [5.85-11.7] \mu\text{m}$, 100 mg/kg/day-administered group ($n = 10$) vs. 1000 mg/kg/day-administered group ($n = 9$), $p = 0.0134$, relative thickness; $0.19 [0.14-0.40]$ vs. $0.51 [0.41-0.74]$, vehicle-treated group ($n = 8$) vs. 1000 mg/kg/day-administered group ($n = 9$), $0.28 [0.23-0.47]$ vs. $0.51 [0.41-0.74]$, 100 mg/kg/day-administered group ($n = 10$) vs. 1000 mg/kg/day-administered group ($n = 9$), $p = 0.027$) (Fig. 4).

We then assessed the infiltration of macrophages which play the crucial role in the pathogenesis of IAs through mediating chronic inflammation [8, 9, 13, 28, 30–33]. The infiltration of CD68-positive macrophages into IA lesions was significantly suppressed by the administration of EPA ($33.2 [22.1-61.0]$ vs. $0.0 [0.0-22.1]$ cells/ mm^2 , vehicle-treated group ($n = 8$) vs. 1000 mg/kg/day-administered group ($n = 9$), $p = 0.028$, $33.2 [22.1-66.5]$ vs. $0.0 [0.0-22.1]$ cells/ mm^2 , 100 mg/kg/day-

**Fig. 3** (See legend on next page.)

(See figure on previous page.)

Fig. 3 Inhibitory effect of EPA on the size of intracranial aneurysms in a rat model. **a** Plasma concentration of EPA, docosahexaenoic acid (DHA), and arachidonic acid (AA) in rats orally administered EPA. Rats were orally administered EPA (vehicle, $n = 9$, 100 mg/kg/day, $n = 8$, 1000 mg/kg/day, $n = 9$) once a day and, on the 5th day, plasma concentration of EPA, DHA, and AA was measured and the ratio of EPA over AA was also calculated. Data represents box-and-whisker plots. Statistical analysis was done by a Kruskal-Wallis test. $*p < 0.05$. **b, c** Effect of EPA on the size of induced aneurysms. EPA was administered in a rat model subjected to aneurysm induction once a day for 12 days and the size of induced aneurysms at right anterior cerebral-olfactory artery bifurcation was measured after Elastica van Gieson staining (vehicle, $n = 8$, 100 mg/kg/day, $n = 10$, 1000 mg/kg/day, $n = 9$). The representative microscopic images of induced aneurysms with Elastica van Gieson staining in each group are shown in **b**. Bar; 50 μ m. Data represents box-and-whisker plots (**c**). Statistical analysis was done by a Kruskal-Wallis test. $*p < 0.05$. **d** Plasma concentration of Resolvin E1 in rats administered EPA. Rats were orally administered EPA once a day and, after 12 days, plasma concentration of Resolvin E1 was measured by ELISA (vehicle, $n = 8$, 1000 mg/kg/day, $n = 9$). Data represents box-and-whisker plots. Statistical analysis was done by a Mann-Whitney test. $*p < 0.05$

administered group ($n = 10$) vs. 1000 mg/kg/day-administered group ($n = 9$), $p = 0.013$) (Fig. 5).

Anti-inflammatory effect of EPA in RAW264.7 cell line and in a rat model

Referencing the previous report demonstrating endogenous expression of GPR120 in RAW264.7 cell line [11] and considering the crucial role of macrophages in the pathogenesis [9, 30, 31], we used this line to examine the effect of EPA on inflammatory responses observed in vivo (Fig. 5). We first examined whether EPA indeed could modulate LPS-induced inflammation via GPR120. Referencing the previous study that EPA suppresses activation of NF- κ B via GPR120 [11, 34], we examined the effect of exogenous EPA on the phosphorylation of NF- κ B p65 subunit at Serine 536 residue by Western blot analysis. Addition of EPA inhibited LPS-induced phosphorylation of NF- κ B p65 subunit (Ser536) as expected (Fig. 6a and Additional file 1: fig. S4). We next assessed *Ccl2* expression in these cells by RT-PCR analysis considering the pivotal role of macrophages in the pathogenesis [30, 33, 35] and also the inhibition of macrophage infiltration in lesions by EPA (Fig. 5). EPA partially but significantly suppressed LPS-induced *Ccl2* expression consistently with the result in NF- κ B activation (Fig. 6b). Importantly, a selective GPR120 agonist, TUG-891 [36, 37], reproduced the effect of EPA on LPS-induced *Ccl2* expression (Fig. 6b). Since induction of MCP-1 encoded by *Ccl2* leads to the formation of a self-amplifying loop among macrophages to exacerbate inflammatory responses by recruiting more macrophages to the inflammatory microenvironment, which in turn promotes the progression of IAs [9], we next examined whether EPA indeed inhibits MCP-1 expression in vivo in a rat model. As a result, CCL2 expression was induced in IA lesions especially at the adventitia and its expression was remarkably suppressed in IA lesions from EPA-administered rats (Fig. 6c), supporting the in vivo relevance of the in vitro study (Fig. 6a, b).

The absolute values of each parameter are listed in the Additional files 2, 3, 4 and 5: Table S1-S4.

Discussion

In the present study, we used an agonist targeting GPR120, EPA, and suggested the suppressive role of this receptor signaling in the progression of IAs induced in rats (Additional file 1: fig. S5). However, EPA has various sites of action on inflammation beyond being a GPR120 agonist, thus, we failed to provide experimental evidence that EPA exerts its effect on the progression of the disease uniquely via GPR120 because of the lack of a rat line deficient in this receptor. Although in vitro studies supported the anti-inflammatory action of EPA at least partially through GPR120 in macrophages and previous studies consistently demonstrated the crucial role of GPR120 signaling in the EPA-mediated suppression of inflammatory responses [11, 34]. The precise contribution of GPR120 signaling to the pathogenesis remains to be carefully investigated. One of the possible mechanisms underlying EPA-mediated suppression of the disease progression may incorporate metabolites such as resolvins [22–25]. As the plasma concentration of Resolvin E1 was not increased by the administration of EPA in the present study (Fig. 3d), we assumed that EPA directly exerts anti-inflammatory action in IA lesions. Another possibility is that EPA is integrated into the plasma membrane and affects the fluidity of the lipid bilayer presumably leading to changes in shear stress-sensing. To further clarify the role of GPR120 signaling in the progression of the disease, the establishment of a rat line deficient in GPR120 is required.

We have demonstrated the suppressive effect of hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors on the rupture of human IAs [38], and there are also many reports describing similar suppressive effects of non-steroid anti-inflammatory drugs (NSAIDs) [39, 40]. These two classes of drugs both presumably exert an inhibitory effect on the rupture of IAs through their potent anti-inflammatory effect, the anti-NF- κ B effect of statins [41, 42] and the suppression of pro-inflammatory prostaglandin synthesis [43, 44]. The development of a drug therapy to prevent the rupture of IAs by targeting inflammation is thus quite promising. Each group of drugs has, however, adverse effects that requires scrupulous attention when being used as long-




Fig. 4 Inhibitory effect of EPA on the thinning of medial smooth muscle cell layer in lesions. **a–c** Inhibitory effect of EPA on the thinning of medial smooth muscle cell layer. Medial smooth muscle cells in IA lesions from rats treated with vehicle or EPA (100 or 1000 mg/kg/day) for 12 days were visualized by immunostaining for smooth muscle α -actin (SMA), a marker for smooth muscle cells. The representative images from immunohistochemistry for SMA (red), nuclear staining by DAPI (blue) and merged images are shown (**a**). The magnified images corresponding to the squares are shown on a right (**a**). Bar; 50 μm . The thickness of the thinnest portion in the media of IA lesions (**b**) and the relative thickness over that of the distal normal part (**c**) were calculated (vehicle, $n = 8$, 100 mg/kg/day, $n = 10$, 1000 mg/kg/day, $n = 9$). Data represents box-and-whisker plots. Statistical analysis was done by a Kruskal-Wallis test. * $p < 0.05$

term-administered preemptive drugs. HMG-CoA reductase inhibitors decrease serum cholesterol level below the normal limit even healthy individuals but a safety of long time-exposure of such a low serum cholesterol level has not yet

been elucidated, making application of this class of drugs for preventing SAH difficult. In the case of NSAIDs, gastrointestinal toxicity or a bleeding tendency due to interference with the physiological functions of prostanoids, including




Fig. 5 Inhibitory effect of EPA on the infiltration of macrophages in lesions. **a, b** Inhibitory effect of EPA on the infiltration of macrophages in lesions. Macrophages infiltrating in IA lesions from rats treated with vehicle or EPA (100 or 1000 mg/kg/day) for 12 days were visualized by immunostaining for CD68, a marker for macrophages. The representative images from immunohistochemistry for CD68 (green) or SMA, a marker for smooth muscle cells (red), nuclear staining by DAPI (blue) and merged images are shown (**a**). The magnified images corresponding to the squares are also shown in the lower panels (**a**). Bar; 10 μ m. The number of infiltrating macrophages in IA lesions was calculated (vehicle, $n = 8$, 100 mg/kg/day, $n = 10$, 1000 mg/kg/day, $n = 9$). Data represents box-and-whisker plots (**b**). Statistical analysis was done by a Kruskal-Wallis test. * $p < 0.05$

prostaglandins, also makes the development of this class of drugs as therapeutic agents to prevent the onset of SAH quite challenging. With respect to the concern about the bleeding tendency caused by NSAIDs and an application for the treatment of unruptured IAs, there exist controversial

reports, with some of them demonstrating a preventive [39, 40] while others, an exacerbating effect [45], toward SAH. As EPA does not have adverse effects on the disease state or performance status, EPA could serve as a reasonable candidate for the treatment of IAs.




Fig. 6 Suppression of NF-κB activation and CCL2 expression by EPA treatment in vitro. **a** Suppression of LPS-induced NF-κB activation by the pre-treatment with EPA. RAW264.7 cells were treated with EPA (300 μM) for 60 min and then stimulated with LPS (3.3 μg/ml) for additional 10 min. NF-κB activation was then assessed by Western blot analysis using the whole cell lysate. The representative images of Western blot analyses from two independent experiments for phosphorylated form of NF-κB p65 subunit (Ser536), NF-κB p65 subunit or α-tubulin served as an internal control are shown. **b** Suppression of LPS-induced *Ccl2* expression by the pre-treatment with EPA. RAW264.7 cells were treated with EPA (300 μM, $n = 6$) or an agonist for GPR120, TUG-891 (3 μM, $n = 7$), for 60 min and then stimulated with LPS (3.3 μg/ml) for additional 60 min. *Ccl2* expression was then assessed by RT-PCR analyses. Data represents mean ± SD. Statistical analysis was done by a Kruskal-Wallis test. * $p < 0.05$. **c** Suppression of CCL2 expression in IA lesions by EPA in rats. EPA (1000 mg/kg/day) was administered in a rat model subjected to aneurysm induction once a day for 12 days and expression of CCL2 in IA lesions was then assessed by immunohistochemistry. The representative images from immunohistochemistry for CCL2 (green), nuclear staining by DAPI (blue), and merged images are shown. The image from immunostaining without a primary antibody for CCL2 is also shown as a negative control study in the lowest panel. Bar: 20 μm

Conclusions

Considering the devastating outcome of SAH due to rupture of IA and the lack of the medical therapy to prevent the progression or rupture of the lesions, the development of the novel medical therapy is mandatory for social health. In the present study, we have identified GPR120 as a GPCR over-expressed in lesions from the comprehensive gene expression profile analyses data using human specimen and also clarified the preventive effect of a GPR120 agonist, EPA, on the progression of the disease using a rat model of IAs. The results of the present study have thus implied the potential of EPA as a drug to prevent the progression of IAs.

Supplementary information

Supplementary information accompanies this paper at <https://doi.org/10.1186/s12974-020-01802-8>.

Additional file 1: Fig. S1. GPR120 expression in human IA lesions. The representative image of immunostaining for GPR120 using human IA specimen is shown in the left panel. The image from immunostaining without a primary antibody for GPR120 is shown as a negative control study in the right panel. The image in the left panel is the same one used in Fig. 1. Bar; 200 μ m. **Fig. S2.** Temporal change of the concentration of EPA and DHA in plasma of rats orally administered EPA. EPA (1000 mg/kg) was orally administered to rats and the concentration of EPA and DHA in plasma was measured at 1 h (n=3), 6 h (n=3) or 24 h (n=4) after the administration. Data represents mean $\pm$ SD. Statistical analysis was done by a Mann-Whitney test. *, p<0.05. Note that the plasma concentration of DHA was not increased by the administration of EPA. **Fig. S3.** Body weight and systemic blood pressure of rats treated with EPA. Rats were subjected to surgical manipulations to induce IAs and then given vehicle or EPA (100 or 1000 mg/kg/day) for 12 days. Body weight (the left panel) and systemic blood pressure (the right panel) were then measured (vehicle, n=9, 100 mg/kg/day, n=10, 1000 mg/kg/day, n=9). Data represents mean $\pm$ SD. Statistical analysis was done by a Kruskal-Wallis test. **Fig. S4.** Full-scanned images of western blot analysis in Fig. 6a. RAW264.7 cells were treated with EPA (300 μ M) for 60 min and then stimulated with LPS (3.3 μ g/ml) for additional 10 min. NF- κ B activation was then assessed by western blot analysis using the whole cell lysate. The whole membranes of the western blot analysis presented in Fig. 6a are shown. Protein molecular weight markers are also displayed on both sides. **Fig. S5.** The graphical abstract of the suppressive effects of EPA on the progression of IAs. The one of the major mechanisms underlying the suppressive effect of EPA on the progression of IAs is the inhibition of inflammation by macrophages through interfering NF- κ B activation via GPR120. Note the interruption of the MCP-1-mediated self-amplification loop among macrophages by EPA. In addition, anti-inflammatory effect of EPA via GPR120 expressed on endothelial cells and the disturbance of wall shear stress-sensing due to the integration of EPA into lipid bilayer in this cell type may also suppress the progression of IAs.

Additional file 2: Table S1. The raw data corresponding to Fig. 3a.

Additional file 3: Table S2. The raw data corresponding to Fig. 3b-d, Fig. 4, Fig. 5, and fig. S3.

Additional file 4: Table S3. The raw data corresponding to fig. S2.

Additional file 5: Table S4. The raw data corresponding to fig. S3.

Abbreviations

AA: Arachidonic acid; ACA: Anterior cerebral artery; BCA: Bicinchoninic acid; CCL2: C-C motif chemokine 2; DAB: 3,3'-Diaminobenzidine; DAPI: 4',6-Diamidino-2-phenylindole dihydrochloride; DHA: Docosahexaenoic acid; DMEN: Dulbecco's modified Eagle medium; EPA: Eicosapentaenoic acid; FFAR4: Free fatty acid receptor 4; GPCRs: G-protein coupled receptors;

GPR120: G-protein coupled receptor 120; HMG-CoA: Hydroxymethylglutaryl-coenzyme A; IA: Intracranial aneurysm; IEL: Internal elastic lamina; IKK β : Inhibitor of kappa B kinase subunit β ; LPS: Lipopolysaccharide; MCP-1: Monocyte chemoattractant protein 1; NSAIDs: Non-steroid anti-inflammatory drugs; NF- κ B: Nuclear factor-kappa B; OA: Olfactory artery; SAH: Subarachnoid hemorrhage; SDS-PAGE: Sodium dodecyl sulfate-polyacrylamide gel electrophoresis; SMA: Smooth muscle α -actin; TAB1: Transforming growth factor- β activated kinase 1 binding protein; TAK1: Transforming growth factor- β activated kinase 1; TGF- β : Transforming growth factor- β

Acknowledgements

Not applicable.

Authors' contributions

YA, TA, and AI planned the experiments. AK and KT acquired human specimen. YA, IO, HK, HM, KS, MO, MK, and TA acquired the data. YA, IO, HK, HM, KS, MO, MK, and TA interpreted the data. YA and TA wrote the manuscript. SM, HK, AI, and TA critically reviewed and modified the manuscript. All authors read and approved the final manuscript.

Funding

This work was supported by Core Research for Evolutional Science and Technology (CREST) on Mechanobiology from the Japan Agency for Medical Research and Development (AMED) (grant ID: JP18gm0810006 and #19gm0810006, T.A.).

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Ethics approval and consent to participate

The use of human samples in the present research was approved by the local ethical committee at Kyoto University Graduate School of Medicine where samples were analyzed (Approval Number: R0456, R0601) and Tokyo Women's Medical University Yachiyo Medical Center (Approval Number: 4106) and Asahikawa Red Cross Hospital (Approval Number: 201441-2) where samples were prepared. Also the written informed consent was obtained from each case. All experiments including animal care and use complied with the National Institute of Health's Guide for the Care and Use of Laboratory Animals and were approved by the Institutional Animal Care and Use Committee of National Cerebral and Cardiovascular Center.

Consent for publication

Not applicable.

Competing interests

M.K. is supported by Core Research for Evolutional Science and Technology (CREST) on Mechanobiology from the Japan Agency for Medical Research and Development (AMED) (#JP18gm0810006 and #19gm0810006, T.A.). Other authors than M.K. declare that they have no competing interests.

Author details

¹Department of Molecular Pharmacology, Research Institute, National Cerebral and Cardiovascular Center, Suita, Osaka 564-8565, Japan.

²Department of Neurosurgery, Kyoto University Graduate School of Medicine, Kyoto, Japan. ³Core Research for Evolutional Science and Technology (CREST) from Japan Agency for Medical Research and Development (AMED), National Cerebral and Cardiovascular Center, Osaka, Japan. ⁴Department of Neurosurgery, Tokyo Women's Medical University Yachiyo Medical Center, Chiba, Japan. ⁵Department of Neurosurgery, Asahikawa Red Cross Hospital, Hokkaido, Japan. ⁶Department of Neurosurgery, The Jikei University Hospital, Tokyo, Japan. ⁷Department of Neurosurgery, Shiga University of Medical Science, Shiga, Japan. ⁸Department of Neurosurgery, Tokyo Women's Medical University, Tokyo, Japan. ⁹Department of Neurosurgery, Showa University, Tokyo, Japan.

Received: 19 December 2019 Accepted: 2 April 2020

Published online: 24 April 2020

References

- van Gijn J, Kerr RS, Rinkel GJ. Subarachnoid haemorrhage. *Lancet*. 2007;369:306–18.
- Huang J, van Gelder JM. The probability of sudden death from rupture of intracranial aneurysms: a meta-analysis. *Neurosurgery*. 2002;51:1101–5 discussion 1105–1107.
- de Rooij NK, Linn FH, van der Plas JA, Algra A, Rinkel GJ. Incidence of subarachnoid haemorrhage: a systematic review with emphasis on region, age, gender and time trends. *J Neurol Neurosurg Psychiatry*. 2007;78:1365–72.
- Etminan N, Chang HS, Hackenberg K, de Rooij NK, Vergouwen MDI, Rinkel GJE, Algra A. Worldwide incidence of aneurysmal subarachnoid hemorrhage according to region, time period, blood pressure, and smoking prevalence in the population: a systematic review and meta-analysis. *JAMA Neurol*. 2019;76:588–97.
- Rinkel GJ, Dijkstra M, Algra A, van Gijn J. Prevalence and risk of rupture of intracranial aneurysms: a systematic review. *Stroke*. 1998;29:251–6.
- Greving JP, Wermer MJ, Brown RD Jr, Morita A, Juvela S, Yonekura M, Ishibashi T, Torner JC, Nakayama T, Rinkel GJ, Algra A. Development of the PHASES score for prediction of risk of rupture of intracranial aneurysms: a pooled analysis of six prospective cohort studies. *Lancet Neurol*. 2014;13:59–66.
- Chalouhi N, Ali MS, Jabbour PM, Tjoumakaris SI, Gonzalez LF, Rosenwasser RH, Koch WJ, Dumont AS. Biology of intracranial aneurysms: role of inflammation. *J Cereb Blood Flow Metab*. 2012;32:1659–76.
- Aoki T, Kataoka H, Shimamura M, Nakagami H, Wakayama K, Moriwaki T, Ishibashi R, Nozaki K, Morishita R, Hashimoto N. NF- κ B is a key mediator of cerebral aneurysm formation. *Circulation*. 2007;116:2830–40.
- Aoki T, Frosen J, Fukuda M, Bando K, Shioi G, Tsuji K, Ollikainen E, Nozaki K, Laakkonen J, Narumiya S. Prostaglandin E2-EP2-NF- κ B signaling in macrophages as a potential therapeutic target for intracranial aneurysms. *Sci Signal*. 2017;10.
- Aoki T, Koseki H, Miyata H, Itoh M, Kawaji H, Takizawa K, Kawashima A, Ujiiie H, Higa T, Minamimura K, et al. RNA sequencing analysis revealed the induction of CCL3 expression in human intracranial aneurysms. *Sci Rep*. 2019;9:10387.
- Oh DY, Talukdar S, Bae EJ, Imamura T, Morinaga H, Fan W, Li P, Lu WJ, Watkins SM, Olefsky JM. GPR120 is an omega-3 fatty acid receptor mediating potent anti-inflammatory and insulin-sensitizing effects. *Cell*. 2010;142:687–98.
- Oh DY, Walenta E. Omega-3 Fatty Acids and FFAR4. *Front Endocrinol (Lausanne)*. 2014;5:115.
- Aoki T, Nishimura M, Matsuoka T, Yamamoto K, Furuyashiki T, Kataoka H, Kitaoka S, Ishibashi R, Ishibazawa A, Miyamoto S, et al. PGE(2)-EP(2) signalling in endothelium is activated by haemodynamic stress and induces cerebral aneurysm through an amplifying loop via NF- κ B. *Br J Pharmacol*. 2011;163:1237–49.
- Schneider CA, Rasband WS, Elieci KW. NIH image to ImageJ: 25 years of image analysis. *Nat Methods*. 2012;9:671–5.
- Terano T, Salmon JA, Higgs GA, Moncada S. Eicosapentaenoic acid as a modulator of inflammation. Effect on prostaglandin and leukotriene synthesis. *Biochem Pharmacol*. 1986;35:779–85.
- Sane S, Baba M, Kusano C, Shirao K, Andoh T, Kamada T, Aikou T. Eicosapentaenoic acid reduces pulmonary edema in endotoxemic rats. *J Surg Res*. 2000;93:21–7.
- Figueras M, Olivan M, Busquets S, Lopez-Soriano FJ, Argiles JM. Effects of eicosapentaenoic acid (EPA) treatment on insulin sensitivity in an animal model of diabetes: improvement of the inflammatory status. *Obesity (Silver Spring)*. 2011;19:362–9.
- Kanda Y. Investigation of the freely available easy-to-use software 'EZ' for medical statistics. *Bone Marrow Transplant*. 2013;48:452–8.
- Hirasawa A, Tsumaya K, Awaji T, Katsuma S, Adachi T, Yamada M, Sugimoto Y, Miyazaki S, Tsujimoto G. Free fatty acids regulate gut incretin glucagon-like peptide-1 secretion through GPR120. *Nat Med*. 2005;11:90–4.
- Gregory MK, Gibson RA, Cook-Johnson RJ, Cleland LG, James MJ. Elongase reactions as control points in long-chain polyunsaturated fatty acid synthesis. *PLoS One*. 2011;6:e29662.
- Moore SA, Hurt E, Yoder E, Sprecher H, Spector AA. Docosahexaenoic acid synthesis in human skin fibroblasts involves peroxisomal retroconversion of tetracosahexaenoic acid. *J Lipid Res*. 1995;36:2433–43.
- Serhan CN, Clish CB, Brannon J, Colgan SP, Chiang N, Gronert K. Novel functional sets of lipid-derived mediators with antiinflammatory actions generated from omega-3 fatty acids via cyclooxygenase 2-nonsteroidal antiinflammatory drugs and transcellular processing. *J Exp Med*. 2000;192:1197–204.
- Arita M, Bianchini F, Aliberti J, Sher A, Chiang N, Hong S, Yang R, Petasis NA, Serhan CN. Stereochemical assignment, antiinflammatory properties, and receptor for the omega-3 lipid mediator resolvin E1. *J Exp Med*. 2005;201:713–22.
- Oh SF, Dona M, Fredman G, Krishnamoorthy S, Irimia D, Serhan CN. Resolvin E2 formation and impact in inflammation resolution. *J Immunol*. 2012;188:4527–34.
- Isobe Y, Arita M, Matsueda S, Iwamoto R, Fujihara T, Nakanishi H, Taguchi R, Masuda K, Sasaki K, Urabe D, et al. Identification and structure determination of novel anti-inflammatory mediator resolvin E3, 17,18-dihydroxyeicosapentaenoic acid. *J Biol Chem*. 2012;287:10525–34.
- Serhan CN, Levy BD. Resolvins in inflammation: emergence of the pro-resolving superfamily of mediators. *J Clin Invest*. 2018;128:2657–69.
- Ishihara T, Yoshida M, Arita M. Omega-3 fatty acid-derived mediators that control inflammation and tissue homeostasis. *Int Immunol*. 2019;31:559–67.
- Frosen J, Piippo A, Paetau A, Kangasniemi M, Niemela M, Hernesniemi J, Jaaskelainen J. Remodeling of saccular cerebral artery aneurysm wall is associated with rupture: histological analysis of 24 unruptured and 42 ruptured cases. *Stroke*. 2004;35:2287–93.
- Inci S, Spetzler RF. Intracranial aneurysms and arterial hypertension: a review and hypothesis. *Surg Neurol*. 2000;53:530–40 discussion 540–532.
- Aoki T, Kataoka H, Ishibashi R, Nozaki K, Egashira K, Hashimoto N. Impact of monocyte chemoattractant protein-1 deficiency on cerebral aneurysm formation. *Stroke*. 2009;40:942–51.
- Koseki H, Miyata H, Shimo S, Ohno N, Mifune K, Shimano K, Yamamoto K, Nozaki K, Kasuya H, Narumiya S, Aoki T. Two diverse hemodynamic forces, a mechanical stretch and a high wall shear stress, determine intracranial aneurysm formation. *Transl Stroke Res*. 2019.
- Fukuda M, Aoki T. Molecular basis for intracranial aneurysm formation. *Acta Neurochir Suppl*. 2015;120:13–5.
- Kanematsu Y, Kanematsu M, Kurihara C, Tada Y, Tsou TL, van Rooijen N, Lawton MT, Young WL, Liang EI, Nuki Y, Hashimoto T. Critical roles of macrophages in the formation of intracranial aneurysm. *Stroke*. 2011;42:173–8.
- Yamada H, Umemoto T, Kakei M, Momomura SI, Kawakami M, Ishikawa SE, Hara K. Eicosapentaenoic acid shows anti-inflammatory effect via GPR120 in 3T3-L1 adipocytes and attenuates adipose tissue inflammation in diet-induced obese mice. *Nutr Metab (Lond)*. 2017;14:33.
- Aoki T, Narumiya S. Prostaglandins and chronic inflammation. *Trends Pharmacol Sci*. 2012;33:304–11.
- Shimpukade B, Hudson BC, Hovgaard CK, Milligan G, Ulven T. Discovery of a potent and selective GPR120 agonist. *J Med Chem*. 2012;55:4511–5.
- Hudson BD, Shimpukade B, Mackenzie AE, Butcher AJ, Pediani JD, Christiansen E, Heathcote H, Tobin AB, Ulven T, Milligan G. The pharmacology of TUG-891, a potent and selective agonist of the free fatty acid receptor 4 (FFA4/GPR120), demonstrates both potential opportunity and possible challenges to therapeutic agonism. *Mol Pharmacol*. 2013;84:710–25.
- Yoshimura Y, Murakami Y, Saitoh M, Yokoi T, Aoki T, Miura K, Ueshima H, Nozaki K. Statin use and risk of cerebral aneurysm rupture: a hospital-based case-control study in Japan. *J Stroke Cerebrovasc Dis*. 2014;23:343–8.
- Hasan DM, Mahaney KB, Brown RD Jr, Meissner I, Piepgras DG, Huston J, Capuano AW, Torner JC. Aspirin as a promising agent for decreasing incidence of cerebral aneurysm rupture. *Stroke*. 2011;42:3156–62.
- Gross BA, Rosalind Lai PM, Frerichs KU, Du R. Aspirin and aneurysmal subarachnoid hemorrhage. *World Neurosurg*. 2014;82:1127–30.
- Aoki T, Kataoka H, Ishibashi R, Nakagami H, Nozaki K, Morishita R, Hashimoto N. Pitavastatin suppresses formation and progression of cerebral aneurysms through inhibition of the nuclear factor κ B pathway. *Neurosurgery*. 2009;64:357–65 discussion 365–356.
- Aoki T, Kataoka H, Ishibashi R, Nozaki K, Hashimoto N. Simvastatin suppresses the progression of experimentally induced cerebral aneurysms in rats. *Stroke*. 2008;39:1276–85.
- Chalouhi N, Starke RM, Correa T, Jabbour PM, Zanaty M, Brown RD Jr, Torner JC, Hasan DM. Differential sex response to aspirin in decreasing aneurysm rupture in humans and mice. *Hypertension*. 2016;68:411–7.

44. Li S, Wang D, Tian Y, Wei H, Zhou Z, Liu L, Wang D, Dong JF, Jiang R, Zhang J. Aspirin inhibits degenerative changes of aneurysmal wall in a rat model. *Neurochem Res.* 2015;40:1537–45.
45. Garbe E, Kreisel SH, Behr S. Risk of subarachnoid hemorrhage and early case fatality associated with outpatient antithrombotic drug use. *Stroke.* 2013;44:2422–6.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:


- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions



Fig.S1



the same image as Figure 1

Fig.S2




Fig.S3




Fig.S4




Fig.S5




Table S1: The raw data corresponding to Fig. 3a

treatment for 5 days	animal ID	volume of plasma (ml)	plasma concentration of AA (ng/ml)	plasma concentration of EPA (ng/ml)	plasma concentration of DHA (ng/ml)	EPA/AA
4ml/kg/day of olive oil (vehicle)	V1	2.0	289.6	29.8	88.0	0.10
	V2	2.3	257.1	11.9	46.0	0.05
	V3	2.3	360.2	35.7	88.9	0.10
	V4	0.6	208.4	11.2	52.6	0.05
	V5	2.2	259.7	14.2	61.3	0.05
	V6	1.7	283.7	22.5	75.2	0.08
	V7	1.7	345.4	16.3	89.2	0.05
	V8	0.6	296.2	30.0	87.1	0.10
	V9	1.9	292.4	12.7	66.8	0.04
100mg/kg/day of EPA	LD1	2.1	210.2	25.5	99.2	0.12
	LD2	1.8	204.6	33.1	50.9	0.16
	LD3	2.1	286.4	31.6	162.3	0.11
	LD4	2.3	335.0	51.4	94.1	0.15
	LD5	1.7	308.1	28.8	59.0	0.09
	LD6	2.1	325.7	32.8	77.7	0.10
	LD8	1.8	306.8	34.6	74.7	0.11
	LD9	2.0	248.7	28.8	64.8	0.12
1000mg/kg/day of EPA	HD1	2.4	157.7	58.3	48.6	0.37
	HD3	1.8	197.0	53.0	67.8	0.27
	HD4	2.3	155.6	44.0	44.9	0.28
	HD5	2.7	172.0	87.6	49.9	0.51
	HD6	2.0	219.3	104.9	68.2	0.48
	HD7	1.8	372.4	181.4	162.9	0.49
	HD8	2.5	215.6	74.3	70.0	0.34
	HD9	1.9	211.9	68.0	54.7	0.32
	HD10	2.5	230.1	91.0	97.8	0.40

Table S2. The raw data corresponding to Fig. 3b-d, Fig. 4, Fig. 5, and fig. S3

treatment for 12 days	animal ID	body weight (g) pre-treatment	body weight (g) post-treatment	Δbody weight (g)	average systolic blood pressure (mmHg) post-treatment	Area of I(A)(μm ²)	thickness of media in the thinnest portion (μm)	thickness of media in the normal portion (μm)	relative thickness thinnest/normal	CD68 positive cell count	number of CD68 positive cells (1/mm ²)	volume of plasma (ml)	plasma concentration of Resolvin E1 (ng/ml)
4ml/kg/day of olive oil (vehicle)	V11	228.0	278.0	50.0	136.3	246.2	7.2	15.9	0.45	3	66.6	2.6	1.355
	V12	238.0	274.0	36.0	154.0	282.5	2.4	11.8	0.20	3	66.6	2.4	4.984
	V13	226.0	256.0	30.0	122.3	452.8	2.9	15.7	0.19	1	22.2	2.1	1.437
	V14	236.0	278.0	42.0	129.7	104.1	7.7	12.4	0.62	1	22.2	2.1	3.769
	V16	242.0	316.0	74.0	154.3	242.4	1.3	15.0	0.09	2	44.4	1.3	4.481
	V17	238.0	286.0	48.0	123.7	215.4	3.3	16.8	0.20	1	22.2	2.6	0.963
	V18	232.0	280.0	48.0	126.7	545.9	4.9	19.5	0.25	0	0.0	2.6	3.766
	V19	230.0	270.0	40.0	126.7	303.0	2.2	17.2	0.13	2	44.4	2.7	1.401
	V20	236.0	286.0	50.0	125.7	173.9	3.9	14.2	0.28	3	66.6	3.2	-
	LD11	222.0	270.0	48.0	127.0	308.9	1.9	15.1	0.12	3	66.6	2.6	-
100mg/kg/day	LD12	232.0	272.0	40.0	136.7	1276.5	3.7	15.8	0.24	3	66.6	2.6	-
	LD13	218.0	286.0	68.0	124.0	231.2	7.4	15.9	0.47	3	66.6	2.3	-
	LD14	216.0	254.0	38.0	139.7	264.7	4.3	15.6	0.27	2	44.4	2.9	-
	LD15	228.0	270.0	42.0	132.7	416.5	5.1	10.5	0.48	0	0.0	2.9	-
	LD16	236.0	280.0	44.0	122.7	144.5	8.9	12.3	0.73	1	22.2	2.5	-
	LD17	234.0	272.0	38.0	153.0	21.7	4.2	19.5	0.22	1	22.2	0.0	-
	LD18	222.0	274.0	52.0	134.0	327.2	3.8	12.7	0.30	1	22.2	3.5	-
	LD19	228.0	262.0	34.0	137.3	122.4	4.6	16.2	0.29	1	22.2	2.6	-
	LD20	230.0	258.0	28.0	132.0	74.5	9.2	18.0	0.51	0	0.0	3.0	1.039
	HD11	228.0	270.0	42.0	116.3	255.8	5.8	12.3	0.47	1	22.2	3.2	0.717
1000mg/kg/day	HD12	242.0	260.0	18.0	135.0	277.1	7.9	11.9	0.66	1	22.2	2.5	0.555
	HD13	234.0	268.0	34.0	124.0	35.8	4.4	12.2	0.36	0	0.0	2.8	0.571
	HD15	236.0	300.0	64.0	124.0	104.7	8.8	18.6	0.47	0	0.0	3.2	1.377
	HD16	236.0	278.0	42.0	130.3	97.8	6.0	16.7	0.36	0	0.0	2.9	1.297
	HD17	234.0	276.0	42.0	138.3	200.9	12.0	16.4	0.73	1	22.2	2.7	1.498
	HD18	230.0	280.0	50.0	135.7	23.4	11.5	15.2	0.76	0	0.0	3.0	0.415
	HD19	230.0	288.0	58.0	150.0	0.0	15.6	18.1	0.86	0	0.0	2.2	4.729
	HD20	234.0	240.0	6.0	128.0	0.0	15.6	18.1	0.86	0	0.0	2.2	4.729

Table S3: The raw data corresponding to fig. S2

treatment	animal ID	volume of the whole blood (ml)				plasma concentration (µg/ml)	
		0 h	1 h	6 h	24 h	EPA	DHA
No EPA or Olive oil (control)	C-1	6				33.6	122.2
	C-2	7				32.4	152.5
	C-3	7				29.4	132.7
	C-4	6.5				36.0	130.2
4ml/kg/day of olive oil (vehicle)	V-1			7		27.1	104.0
	V-2			6.5		30.0	89.8
	V-3			8		28.2	126.6
	V-4				8	43.8	105.6
	V-5				8	29.2	107.4
	V-6				7	30.2	86.9
	V-7				8	35.7	103.3
	V-8		8			39.5	105.9
	V-9		7			39.3	125.5
	V-10		5			35.8	114.1
1000mg/kg of EPA	E-1			7.8		198.2	100.3
	E-2			8		207.5	88.0
	E-3			3		317.3	86.3
	E-4				7	111.5	111.8
	E-5				7	131.8	104.5
	E-6				7	114.2	64.6
	E-7				8	102.0	114.6
	E-8		5			169.2	121.5
	E-9		7			122.2	97.0
	E-10		8			125.7	158.4

Table S4: The raw data corresponding to fig. S3

treatment for 12 days	animal ID	heart rate (1/min)	systolic blood pressure (mmHg)	mean blood pressure (mmHg)	diastolic blood pressure (mmHg)
4ml/kg/day of olive oil (vehicle)	V11	412	139	112	98
		394	135	110	98
		404	135	112	101
	V12	403	157	126	110
		398	152	125	112
		405	153	131	120
	V13	350	121	95	82
		338	122	97	85
		339	124	95	81
	V14	367	128	107	97
		372	133	111	100
		364	128	107	97
	V16	395	139	146	135
		406	162	137	125
		393	162	137	125
	V17	402	125	107	98
		387	122	106	98
		403	124	109	102
	V18	394	122	98	86
		400	122	101	91
		400	118	99	90
	V19	363	129	106	95
		370	127	103	90
		358	124	104	94
	V20	401	129	107	96
		388	125	104	94
		390	123	104	94
100mg/kg/day	LD11	388	128	109	100
		390	128	112	104
		393	125	108	100
	LD12	407	139	114	102
		401	128	111	103
		401	143	113	98
	LD13	435	124	106	97
		428	121	104	96
		436	127	102	90
	LD14	401	144	113	98
		413	139	111	97
		411	136	109	96
	LD15	348	134	106	92
		351	131	108	91
		351	133	108	96
	LD16	341	124	102	91
		344	123	100	89
		342	121	104	96
	LD17	437	153	123	108
		454	153	129	117
		440	153	124	110
	LD18	364	137	115	103
		362	133	115	106
		363	132	112	102
	LD19	390	143	107	89
		402	137	107	92
		391	132	103	89
	LD20	440	131	115	106
		442	135	115	105
		435	130	114	106
1000mg/kg/day	HD11	349	118	98	88
		352	112	94	85
		349	119	99	89
	HD12	432	139	108	93
		429	132	107	94
		434	134	105	91
	HD13	356	123	94	80
		357	128	96	80
		353	121	98	87
	HD15	401	124	98	85
		401	124	97	87
		401	124	98	84
	HD16	403	129	104	92
		400	134	112	101
		403	128	111	103
	HD17	385	136	103	100
		396	139	113	103
		382	140	122	113
	HD18	402	130	102	88
		407	134	102	86
		389	143	111	95
	HD19	426	153	125	111
		422	151	127	115
		426	146	121	108
	HD20	412	123	109	102
		412	132	109	98
		408	129	109	99